首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3777篇
  免费   272篇
  国内免费   32篇
耳鼻咽喉   5篇
儿科学   118篇
妇产科学   8篇
基础医学   67篇
口腔科学   1篇
临床医学   614篇
内科学   2321篇
皮肤病学   1篇
神经病学   8篇
特种医学   64篇
外科学   568篇
综合类   205篇
预防医学   25篇
眼科学   2篇
药学   39篇
  1篇
中国医学   31篇
肿瘤学   3篇
  2023年   126篇
  2022年   187篇
  2021年   336篇
  2020年   291篇
  2019年   297篇
  2018年   247篇
  2017年   116篇
  2016年   83篇
  2015年   150篇
  2014年   301篇
  2013年   229篇
  2012年   130篇
  2011年   151篇
  2010年   114篇
  2009年   104篇
  2008年   132篇
  2007年   91篇
  2006年   100篇
  2005年   77篇
  2004年   67篇
  2003年   48篇
  2002年   58篇
  2001年   45篇
  2000年   46篇
  1999年   37篇
  1998年   45篇
  1997年   43篇
  1996年   34篇
  1995年   53篇
  1994年   48篇
  1993年   37篇
  1992年   34篇
  1991年   36篇
  1990年   27篇
  1989年   21篇
  1988年   12篇
  1987年   20篇
  1986年   17篇
  1985年   17篇
  1984年   20篇
  1983年   17篇
  1982年   11篇
  1981年   7篇
  1980年   2篇
  1979年   6篇
  1978年   4篇
  1976年   2篇
  1975年   3篇
  1974年   2篇
排序方式: 共有4081条查询结果,搜索用时 15 毫秒
1.
目的分析半夏泻心汤对Hp相关性胃炎患者疗效与安全性。方法选取2018年6月—2020年3月江西省黎川县人民医院收治的Hp相关性胃炎患者90例为研究对象,按照随机单双数法分为对照组45例为常规性治疗,观察组45例采用半夏泻心汤治疗,对比2种不同治疗方式下患者总有效率和不良反应率。结果观察组治疗后总有效率高于对照组,差异有统计学意义(P<0.05);观察组治疗后不良反应率和对照组比较,差异无统计学意义(P>0.05);治疗前2组患者腹胀、乏力评分差异较小(P>0.05);观察组治疗后中医证候评分显著低于对照组,差异有统计学意义(P<0.05)。结论采用半夏泻心汤治疗Hp相关性胃炎患者可有效提升疾病治疗效果,减少不良反应率,有临床应用价值。  相似文献   
2.
BackgroundRecent guidelines for the treatment of moderate or severe ischemic mitral regurgitation (IMR) in patients undergoing coronary artery bypass grafting (CABG) have changed. This study assessed the real-world impact of changing guidelines on the management of IMR during CABG over time. We hypothesized that the utilization of mitral valve repair for IMR would decrease over time, whereas mitral valve replacement for severe IMR would increase.MethodsPatients undergoing CABG in a statewide collaborative database (2011-2020) were stratified by severity of IMR. Trends in mitral valve repair or replacement were evaluated. To account for differences of the patients, propensity score–matched analyses were used to compare patients with and without mitral intervention.ResultsA total of 11,676 patients met inclusion criteria, including 1355 (11.6%) with moderate IMR and 390 (3.3%) with severe IMR. The proportion of patients undergoing mitral intervention for moderate IMR decreased over time (2011, 17.7%; 2020, 7.5%; Ptrend = .001), whereas mitral replacement for severe IMR remained stable (2011, 11.1%; 2020, 13.3%; Ptrend = .14). Major morbidity was higher for patients with moderate IMR who underwent mitral intervention (29.1% vs 19.9%; P = .005). In a propensity analysis of 249 well-matched pairs, there was no difference in major morbidity (29.3% with mitral intervention vs 23.7% without; P = .16) or operative mortality (1.2% vs 2.4%; P = .5).ConclusionsConsistent with recent guideline updates, patients with moderate IMR were less likely to undergo mitral repair. However, the rate of replacement for severe IMR did not change. Mitral intervention during CABG did not increase operative mortality or morbidity.  相似文献   
3.
4.
5.
6.
目的分析使用J-ValveTM系统行经心尖主动脉瓣置换术(transapical aortic valve implantation,TA-TAVI)治疗高危主动脉瓣关闭不全患者的中期临床预后。方法回顾性收集2016年9月至2020年6月在浙江大学医学院附属第二医院连续收治的25例使用J-ValveTM系统经心尖TAVI治疗的主动脉瓣关闭不全患者资料,分析总结术后全因病死率,不良事件发生率及心功能改善情况。结果25例中男19例,年龄范围为59~83岁,平均年龄(72.3±27.11)岁。经胸超声心动图检查评估重度主动脉瓣反流比例达88%,心功能(NYHA分级)Ⅲ-Ⅳ级占92%。患者最常合并的基础病为高血压(占68%),合并冠心病5例,既往心脏手术史3例,术前胸外科医师协会(the Society of Thoracic Surgeons,STS)评分为1.511%~27.674%,中位STS评分为4.27(2.914~6.033)%。手术均成功置入J-Valve瓣膜,无中转开胸。术后置入永久起搏器2例,CRRT 1例,中度及以上瓣周漏1例。手术早期疗效可观,不良事件发生率低,中期随访心功能及心室逆重构也有持续改善表现。结论对于高危主动脉瓣关闭不全患者使用J-ValveTM系统行经心尖TAVI可获得较好的围手术期安全性及中期预后。  相似文献   
7.
BackgroundProsthetic choice for mitral valve replacement is generally driven by patient age and patient and surgeon preference, and current guidelines do not discriminate between different etiologies of mitral valve disease. Our objective was to assess and compare short- and long-term outcomes after mitral valve replacement among patients with biological or mechanical prostheses in the setting of severe ischemic mitral regurgitation.MethodsBetween 2000 and 2016, 424 patients underwent mitral valve replacement for severe ischemic mitral regurgitation at our institution, using biological prosthesis in 188 (44%) and mechanical prosthesis in 236 (56%). A 1:1 propensity score match (n = 126 per group) and inverse probability of treatment weighting were used to compare groups. Short-term outcomes included in-hospital mortality and other cardiovascular adverse events. Long-term outcomes included survival and hospital readmission for cardiovascular causes, stroke, and major bleeding.ResultsIn-hospital mortality and early postoperative adverse events were similar between groups in the propensity score match and inverse probability of treatment weighting cohorts. Overall long-term survival was similar at 5 and 9 years, but mechanical prosthesis recipients were more frequently readmitted to hospital for cardiovascular causes, including stroke and non-neurological bleeding in propensity score matching and inverse probability of treatment weighting analyses (all P values < .004). Type of prosthesis did not independently influence all-cause mortality (hazard ratio, 1.01; 95% confidence interval, 0.71-1.43; P = .959), but placement of a mechanical prosthesis was associated with increased risk of readmission for cardiovascular events (hazard ratio, 1.65; 95% confidence interval, 1.17-2.32; P = .004) among matched patients.ConclusionsThe type of prosthesis has no influence on long-term survival among patients with severe ischemic mitral regurgitation undergoing mitral valve replacement. There may be an increased risk of neurologic events and serious bleeding associated with mechanical prostheses.  相似文献   
8.
Introduction and objectivesTranscatheter edge-to-edge repair (TEER) should be considered in patients with heart failure and secondary mitral regurgitation (MR). Angiotensin receptor-neprilysin inhibitors (ARNIs) have been demonstrated to improve prognosis in heart failure. We aimed to evaluate the impact ARNIs on patient selection and outcomes.MethodsThe population of the Spanish TEER prospective registry (March 2012 to January 2021) was divided into 2 groups: a) TEER before the ARNI era (n = 450) and b) TEER after the recommendation of ARNIs by European Guidelines (n = 639), with further analysis according to intake (n = 52) or not (n = 587) of ARNIs.ResultsA total of 1089 consecutive patients underwent TEER for secondary MR. In the ARNI era, there was a reduction in left ventricle dilation (82 mL vs 100 mL, P = .025), and better function (35% vs 38%, P = .011). At 2 years of follow-up, mortality (10.6% vs 17.3%, P < .001) and heart failure readmissions (16.6% vs 27.8%, P < .001) were lower in the ARNI era, but not recurrent MR. In the ARNI era, 1- and 2-year mortality were similar irrespective of ARNI intake but patients on ARNIs had a lower risk of readmission + mortality at 2 years (OR, 0.369; 95%CI, 0.137-0.992; P = .048), better NYHA class, and lower recurrence of MR III-IV (1.9% vs 14.3%, P = .011).ConclusionsBetter patient selection for TEER has been achieved in the last few years with a parallel improvement in outcomes. The use of ARNIs was associated with a significant reduction in overall events, better NYHA class, and lower MR recurrence.  相似文献   
9.
10.
Infant regurgitation is common during infancy and can cause substantial parental distress. Regurgitation can lead to parental perception that their infant is in pain. Parents often present in general practitioner surgeries, community baby clinics and accident and emergency departments which can lead to financial burden on parents and the health care system. Probiotics are increasingly reported to have therapeutic effects for preventing and treating infant regurgitation. The objective of this systematic review and meta-analysis was to evaluate the efficacy of probiotic supplementation for the prevention and treatment of infant regurgitation. Literature searches were conducted using MEDLINE, CINAHL, and the Cochrane Central Register of Controlled trials. Only randomised controlled trials (RCTs) were included. A meta-analysis was performed using the Cochrane Collaboration methodology where possible. Six RCTs examined the prevention or treatment with probiotics on infant regurgitation. A meta-analysis of three studies showed a statistically significant reduction in regurgitation episodes for the probiotic group compared to the placebo group (mean difference [MD]: ?1.79 episodes/day: 95% confidence interval [CI]: ?3.30 to ?0.27, N = 560), but there was high heterogeneity (96%). Meta-analysis of two studies found a statistically significant increased number of stools per day in the probiotic group compared to the placebo group at 1 month of age (MD: 1.36, 95% CI: 0.99 to 1.73, N = 488), with moderate heterogeneity (69%). Meta-analysis of two studies showed no statistical difference in body weight between the two groups (MD: ?91.88 g, 95% CI: 258.40–74.63: I2 = 23%, N = 112) with minimal heterogeneity 23%. Probiotic therapy appears promising for infant regurgitation with some evidence of benefit, but most studies are small and there was relatively high heterogeneity. The use of probiotics could potentially be a noninvasive, safe, cost effective, and preventative positive health strategy for both women and their babies. Further robust, well controlled RCTs examining the effect of probiotics for infant regurgitation are warranted.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号